Andrea Casini

Andrea Casini

Auto-generated profile, based on publicly available information

Andrea Casini

Vascular Unit, Humanitas Gavazzeni, Bergamo, Italy

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2014 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
EGEdoardo Gronda
Edoardo Gronda
GSGino Seravalle
Gino Seravalle
GBGianmaria Brambilla
Gianmaria Brambilla
GCGiuseppe Costantino
Giuseppe Costantino
ACAndrea Casini
Andrea Casini
GGGuido Grassi
Guido Grassi
Aims Heart failure (HF) pathophysiology is believed to be mediated by autonomic dysfunction, including chronic sympathoexcitation and diminished baroreflex sensitivity, which correlate with mortality risk. Baroreflex activation therapy (BAT) is a device‐based treatment providing chronic baroreflex activation through electrical stimulation of the carotid sinus. BAT chronically reduces sympathetic activity in resistant hypertension. The purpose of this investigation is to determine BAT effects in clinical HF. Methods and results In a single‐centre, open‐label evaluation, patients with NYHA class III HF, EF <40%, optimized medical therapy, and ineligible for cardiac resynchronization received BAT for 6 months. Efficacy was assessed with serial measurement of muscle sympathetic nerve activity (MSNA) and clinical measures of quality of life and functional capacity. Eleven patients participated in the trial. MSNA was reduced over 6 months from 45.1 ± 7.7 to 31.3 ± 8.3 bursts/min and from 67.6 ± 12.7 to 45.1 ± 11.6 bursts/100 heartbeats, decreases of 31% and 33%, respectively (P < 0.01). Concomitant improvements occurred in baroreflex sensitivity, EF, NYHA class, quality of life and 6 min hall walk (6MHW) distance (P ≤ 0.05 each). On an observational basis, hospitalization and emergency department visits for worsening HF were markedly reduced. One complication, perioperative anaemia requiring transfusion, occurred during the study. Conclusion BAT was safe and provided chronic improvement in MSNA and clinical variables. Based on present understanding of HF pathophysiology, these results suggest that BAT may improve outcome in HF by modulating autonomic balance. Prospective, randomized trials to test the hypothesis are warranted.

1 April 2008 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
TLTommaso Lupattelli
Tommaso Lupattelli
JCJacques Clerissi
Jacques Clerissi
GCGiacomo Clerici
Giacomo Clerici
DMDaniela P. Minnella
Daniela P. Minnella
ACAndrea Casini
Andrea Casini
EFEzio Faglia
Ezio Faglia

28 December 2018 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
RFRoberto Ferraresi
Roberto Ferraresi
ACAndrea Casini
Andrea Casini
FLFabrizio Losurdo
Fabrizio Losurdo
MCMaurizio Caminiti
Maurizio Caminiti
AUAlessandro Ucci
Alessandro Ucci
GCGiacomo Clerici
Giacomo Clerici
Purpose: To describe a preliminary experience in treating no-option critical limb ischemia (CLI) patients with a hybrid foot vein arterialization (HFVA) technique combining open plus endovascular approaches. Materials and Methods: Between May 2016 and January 2018, 35 consecutive patients (mean age 68±12 years; 28 men) with 36 no-option CLI limbs underwent HFVA in our center. All limbs had grade 3 WIfI (Wound, Ischemia, and foot Infection) ischemia, and the wound classification was grade 1 in 4 (11%) limbs, grade 2 in 4 (11%), and grade 3 in 28 (78%). Surgical bypass was done on the medial marginal vein or a posterior tibial vein, followed by endovascular removal of foot vein valves and embolization of foot vein collaterals. A “tension-free” surgical approach was used to treat foot lesions. Results: At a mean follow-up of 10.8±2 months, limb salvage was achieved in 25 (69%) limbs and wound healing in 16 (44%); 9 patients presented an unhealed wound. Eleven (31%) patients underwent a major amputation (2 below the knee and 9 thigh). One patient with an unhealed wound and open bypass died of myocardial infarction. Conclusion: HFVA is a promising technique able to achieve acceptable rates of limb salvage and wound healing in no-option patients generally considered candidates for an impending major amputation. Further studies are needed to standardize the technique and better identify patients who can benefit from this approach.

1 August 2001 in Fertility and Sterility
Verified
Journal Article
Closed access
PDF file
MPMaurio Penotti
Maurio Penotti
LSLaura Sironi
Laura Sironi
LCLetizia Cannata
Letizia Cannata
Paola Vigano'Paola Vigano'
Paola Vigano'
ACAndrea Casini
Andrea Casini
MVMario Vignali
Mario Vignali

1 August 2015 in Journal Of Hypertension
Verified
Journal Article
Closed access
EGEdoardo Gronda
Edoardo Gronda
GSGino Seravalle
Gino Seravalle
FTFosca Quarti Trevano
Fosca Quarti Trevano
GCGiuseppe Costantino
Giuseppe Costantino
ACAndrea Casini
Andrea Casini
GGGuido Grassi
Guido Grassi
Baroreflex activation therapy (BAT) has recently been shown to reduce muscle sympathetic nerve activity and hospitalization rate while improving clinical variables through 6 months of therapy in patients with heart failure and reduced ejection fraction (HFrEF). The objective of the present study is to extend the information on this patient cohort over a long-term follow-up. Eleven patients were enrolled in the study and presented with optimized, stable medical therapy, New York Heart Association Class III HFrEF with left ventricular ejection fraction 40% or less, impaired functional capacity and no active cardiac resynchronization therapy. For the present report, muscle sympathetic nerve activity, baroreflex sensitivity data and hospitalization rate together with standard clinical data were collected at 12 and 21.5 ± 4.2 months following BAT activation. Two patients died during long-term follow-up. The remaining nine patients maintained the improvements observed at 6 months, including reduced sympathetic activity and rates of hospitalization. BAT provides long-term chronic reductions in sympathetic activity and utilization of hospital resources in patients with HFrEF. General clinical presentation, quality of life and functional capacity are likewise improved and maintained. The temporal association of BAT with sympathetic drive diminution and improvement in objective clinical measures suggests a cause-and-effect relationship that will be verified in future randomized controlled trials of outcome.

31 August 2010 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
EFEzio Faglia
Ezio Faglia
GCGiacomo Clerici
Giacomo Clerici
MCMaurizio Caminiti
Maurizio Caminiti
VCVincenzo Curci
Vincenzo Curci
JCJacques Clerissi
Jacques Clerissi
AMAlberto Morabito
Alberto Morabito